Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Science Translational Medicine · 14.08.2024 · 16 (760)
DOI: 10.1126/scitranslmed.adi2245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 14.08.2024. Verfasst von Scarlett J Barker und 45 weiteren Autor:innen. Beteiligte Einrichtung: Denali Therapeutics Inc., South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Oligonucleotides, Antisense, Receptors, Transferrin, RNA, Long Noncoding. Die Arbeit wurde bisher 157-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) are promising therapeutics for treating various neurological disorders. However, ASOs are unable to readily cross the mammalian blood-brain barrier (BBB) and therefore need to be delivered intrathecally to the central nervous system (CNS). Here, we engineered a human transferrin receptor 1 (TfR1) binding molecule, the oligonucleotide transport vehicle (OTV), to transport a tool ASO across the BBB in human TfR knockin (TfR mu/hu KI) mice and nonhuman primates. Intravenous injection and systemic delivery of OTV to TfR mu/hu KI mice resulted in sustained knockdown of the ASO target RNA, Malat1 , across multiple mouse CNS regions and cell types, including endothelial cells, neurons, astrocytes, microglia, and oligodendrocytes. In addition, systemic delivery of OTV enabled Malat1 RNA knockdown in mouse quadriceps and cardiac muscles, which are difficult to target with oligonucleotides alone. Systemically delivered OTV enabled a more uniform ASO biodistribution profile in the CNS of TfR mu/hu KI mice and greater knockdown of Malat1 RNA compared with a bivalent, high-affinity TfR antibody. In cynomolgus macaques, an OTV directed against MALAT1 displayed robust ASO delivery to the primate CNS and enabled more uniform biodistribution and RNA target knockdown compared with intrathecal dosing of the same unconjugated ASO. Our data support systemically delivered OTV as a potential platform for delivering therapeutic ASOs across the BBB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Denali Therapeutics Inc., South San Francisco, CA, USA.
- Ionis Pharmaceuticals, Carlsbad, CA, USA.
ORCID-Profile: Scarlett J Barker, Mai B Thayer, Chaeyoung Kim, Matthew J Simon, Rebekah Dial, Lizanne Nilewski, Robert C Wells, Megan Afetian, Alfred Chappell, Kylie S Chew, Johann Chow, Chrissa Dwyer, Timothy Earr, Connie Ha, Srini Jayaraman, Cathal Mahon, Michelle Pizzo, Yaneth Robles-Colmenares, Laura Sanders, Alexander Stergioulis, Raymond Tong, Hai Tran, Y Zuchero, Christopher M M Koth, Pascal E Sanchez, Robert G Thorne, Ryan J Watts, Thomas Sandmann, Lesley A Kane, Mark S Dennis, Joseph W Lewcock, Sarah L DeVos
Zitieren
APA
Barker, S. J., Thayer, M. B., Kim, C., Tatarakis, D., Simon, M. J., Dial, R., Nilewski, L., Wells, R. C., Zhou, Y., Afetian, M., Akkapeddi, P., Chappell, A., Chew, K. S., Chow, J., Clemens, A., Discenza, C. B., Dugas, J. C., Dwyer, C., Earr, T., …, & DeVos, S. L. (2024). Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Science Translational Medicine, 16(760). https://doi.org/10.1126/scitranslmed.adi2245
Vancouver
Barker SJ, Thayer MB, Kim C, Tatarakis D, Simon MJ, Dial R, et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Science Translational Medicine. 2024;16(760). doi:10.1126/scitranslmed.adi2245
BibTeX
@article{Barker2024,
author = {Barker, Scarlett J and Thayer, Mai B and Kim, Chaeyoung and Tatarakis, David and Simon, Matthew J and Dial, Rebekah and Nilewski, Lizanne and Wells, Robert C and Zhou, Yinhan and Afetian, Megan and Akkapeddi, Padma and Chappell, Alfred and Chew, Kylie S and Chow, Johann and Clemens, Allisa and Discenza, Claire B and Dugas, Jason C and Dwyer, Chrissa and Earr, Timothy and Ha, Connie and Ho, Yvonne S and Huynh, David and Lozano, Edwin I and Jayaraman, Srini and Kwan, Wanda and Mahon, Cathal and Pizzo, Michelle and Robles-Colmenares, Yaneth and Roche, Elysia and Sanders, Laura and Stergioulis, Alexander and Tong, Raymond and Tran, Hai and Zuchero, Y and Estrada, Anthony A and Gadkar, Kapil and Koth, Christopher M M and Sanchez, Pascal E and Thorne, Robert G and Watts, Ryan J and Sandmann, Thomas and Kane, Lesley A and Rigo, Frank and Dennis, Mark S and Lewcock, Joseph W and DeVos, Sarah L},
title = {Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {760},
doi = {10.1126/scitranslmed.adi2245}
}
EUVIMED